Short Acting Beta2 Agonists Market: Global Segments, Top Key Players, Size and Recent Trends by Forecast to 2025

Short-acting beta2-agonists (SABA) are a type of bronchodilators. These are the most common immediate-relief drugs for treating asthma attacks and to manage both acute and stable exacerbations of chronic obstructive pulmonary disease (COPD). Salbutamol is the most commonly prescribed short-acting beta2-agonists (SABA) and is available under different brand names such as Salamol, Ventolin, and Proventil. The usage of short-acting beta-2-agonists SABAs on a regular basis for at least seven days in stable COPD is associated with the decrease in breathlessness and improvement in post bronchodilator lung function within 5 minutes. The inhaled form of the drug is available in metered-dose inhalers and as a liquid for compressor-driven nebulizers. Short-acting beta2-agonists (SABA) are utilized to treat symptoms in intermittent asthma, prevent asthma symptoms before exercise, and provide quick relief of symptoms during asthma attacks. A combination of ipratropium and short-acting beta2-agonists (SABA) in severe, acute asthma episodes results in improved lung function and fewer hospital visits

Report Overview @ https://www.transparencymarketresearch.com/short-acting-beta2-agonists-market.html

Short-acting beta2 agonist (SABA) is known as a quick-acting and reliving medication from sudden asthma attacks, as it helps to rapidly open the airways. This is driving the global short acting beta2-agonists (SABA) market. Emergence of biologics to treat severe asthma and novel combination therapies are likely to drive the market. New technological advancements and product innovations lead to increased demand for the Short-acting beta2 agonist (SABA) drugs. However, the expiry of patents and exclusivity of branded drugs are restraining the market. Ability of the drug to keep asthma under control and increasing population suffering from asthma and chronic diseases such as chronic obstructive pulmonary disease are attributed to boost the global short acting beta2-agonists market. According to the World Health organization (WHO), in 2015, 383,000 people died due to asthma. Many asthma-related deaths occur in low- and lower-middle income countries. WHO also stated that approximately 235 million people are presently suffering from asthma, and it is a common disease among children.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33881

WHO estimated that, in 2015, COPD caused 3 million deaths across the world, which accounts to approximately 5% of all deaths. The primary cause of COPD is exposure to tobacco smoke, either passive or active. Expansion of the market is attributed to the popularity and preference for short acting beta2-agonists. However, patent and exclusivity expiry of major selling drugs such as Serevent, restrains the global market. The global short-acting beta2 agonists (SABA) market can be segmented based on dosage form, application type, distribution channel, and region. Based on dosage form, the market can be segregated into solution, injectable, tablet, syrup, and elixir. In terms of the application type, the market can be segmented into Chronic Obstructive Pulmonary Disease (COPD) and asthma. Based on distribution channel, the market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33881

In terms of region, the market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held a prominent share of the market in 2016 due to technological advancements in R&D of short acting beta2-agonists drugs. Europe followed North America in terms of market share in 2016 due to the increased prevalence of asthma. According to Asthma UK, 5.4 million people in the U.K. are currently diagnosed with asthma, approximately 1.1 million children, which accounts to 1 in 11, and 4.3 million adults, which accounts 1 in 12. The market in Asia Pacific, Latin America, and Middle East & Africa is estimated to expand during the forecast period due to the increasing population and air pollution.

Key players operating in the global short acting beta2-agonists (SABA) market include Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Actelion Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, and GlaxoSmithKline plc.

Popular Research Reports by TMR:

Blood Group Typing Market: http://www.prnewswire.co.uk/news-releases/blood-group-typing-market-is-projected-to-reach-us-35560-mn-by-2026-says-tmr-691433291.html

Medical Nonwoven Disposables Market :https://globenewswire.com/news-release/2018/08/08/1549072/0/en/Medical-Nonwoven-Disposables-Market-will-be-Worth-US-18-4-Billion-by-the-End-of-2024.html

Antifibrinolytic Drugs Market: Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2025

Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss in traumatic injuries. These drugs inhibit the activation of plasminogen to plasmin, thus preventing fibrinolysis and maintaining clot stability. Antifibrinolytic drugs are commonly known as fibrinolytic inhibitors. Reduction of fibrinolytic activity with antifibrinolytic drugs is important in trauma and surgery to control blood loss. People suffering from bleeding disorders such as hemophilia A and B, Von Willebrand disease, and platelet dysfunctions are often treated with fibrinolytic inhibitors or antifibrinolytic drugs. Currently, epsilon-aminocaproic acid (EACA) and tranexamic acid (TA or AMCA) are the synthetic antifibrinolytic drugs available in the market. EACA is a synthetic derivative of lysine and has a strong inhibiting effect on plasminogen. TA is found to be 10 times more effective than epsilon-aminocaproic acid.

Report Overview @ https://www.transparencymarketresearch.com/antifibrinolytic-drugs-market.html

The global antifibrinolytic drugs market is anticipated to expand during the forecast period due to rise in severe road accidents, complicated medical surgeries and procedures, prevalence of angioedema, and rise in the high-risk geriatric population globally. Trauma is the second largest cause of death in people aged between five and 45 years. Each year, about three million people die due to trauma. Injuries to the central nervous system and multi-organ failure cause severe bleeding problems. In such cases, antifibrinolytic drugs play a key role in preventing lysis of clot and loss of blood. Antifibrinolytic drugs are given to patients, undergoing cardiovascular surgeries, to prevent excessive bleeding. High prevalence of bleeding disorders and rise in major surgical procedures drive the global antifibrinolytic drugs market.

The global antifibrinolytic drugs market can be segmented based on drug type, application, end-user, and region. In terms of drug type, the global market can be divided into Trasylol, Aminocaproic acid, RiaSTAP, Aprotinin, Tranexamic acid injection, Tranexamic acid oral, Lysteda, and Fibrinogen, human.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34133

Based on application, the global antifibrinolytic drugs market can be categorized into gynecology, gastrointestinal bleeding, hereditary angioedema, hemorrhage, bleeding in nose and mouth, fibrinolytic response testing, and surgeries. The gynecology segment can be further divided into medical conditions such as menorrhagia, pregnancy, parturition, and gynecological surgeries. The surgeries segment includes dental surgeries, cardiovascular surgeries, and neurosurgeries. In terms of end-user, the global antifibrinolytic drugs market can be segmented into hospitals, ambulatory surgical centers, clinics, and health care specialty processes.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34133

In terms of region, the global antifibrinolytic drugs market can be segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa. North America dominates the market in terms of revenue and is anticipated to continue its dominance during the forecast period from 2017 to 2025. Rise in awareness about antifibrinolytic drugs is likely to augment the market in North America. Growth of the market in North America can also be attributed to substantial investments in R&D and health care expenditure by the government and private players. Europe holds the second largest share of the global antifibrinolytic drugs market owing to mandatory medical insurance in countries such as Germany and France, high disposable income, and high research & development in the health care sector. The market in Asia Pacific and Middle East & Africa is attributed to expand at a significant pace during the forecast period.

Key players operating in the global antifibrinolytic drugs market are Acic Fine Chems, Xanodyne Pharmaceuticals, and Aurobindo Pharma Ltd.

Popular Research Reports by TMR:
Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

Polio Market: Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2025

Polio also known as poliomyelitis, is a cause of poliovirus infection. The condition involves inflammation of the spinal cord gray matter. It is an acute infectious disease which is highly contagious via the oral-oral and fecal-oral routes. The infection may even spread into the brainstem leading to polioencephalitis. About 90% of polio infections are known to cause no symptoms; however, it may exhibit symptoms if the virus passed into the blood stream. Polio infections may result into various types of paralysis, depending on the type of nerve infected. Various types of polio include spinal polio, bulbar polio, and bulbospinal polio. Laboratory diagnosis of the disease involves recovery of the poliovirus from stool samples or a swab of the pharynx. Detection of antibodies in the blood against poliovirus may help in the disease diagnosis. There is no known cure for polio, and thus vaccination remains the only preventive measure against this disease.

Report Overview @ https://www.transparencymarketresearch.com/polio-market.html

The global polio market is expected to grow substantially due to targeted and data driven planning, rigorous monitoring and effective communication, skilled and motivated staff, and adequate funding. However, high rates of migration and birth rates, population density, poor sanitation, and low routine immunization rates are likely to pose a challenge to this market. Increasing efforts for vaccination led by the WHO and UNICEF may help the eradication of the disease across the globe. In addition, provision of free vaccination by dedicated workers can lead to complete eradication of the disease. For instance, India was declared polio-free in 2012.

The global market for polio is segmented by vaccine, supportive measure, application, and geography. In terms of vaccine, the market is segmented into inactivated polio vaccine and live attenuated vaccine. The inactivated polio vaccine is administered by using parenteral route, and the live attenuated vaccine is administered by oral route. The live attenuated vaccine segment generates higher revenue than the inactivated polio vaccine segment as the former is easy to administer, and required high dose as compared to parenteral route. Both the vaccines are generally considered safe to give at the time of pregnancy and to those who have HIV/AIDS. The World Health Organization recommends that all children around the world should be vaccinated against polio. In terms of supportive measure, the market is segmented into antibiotics, analgesics, portable ventilators, and rehabilitation therapies such as occupational therapy, braces, orthopedic surgery, corrective shoes, and physical therapy. Based on application, the market for polio is divided into adults and pediatric patients. The pediatric segment is likely to account for a significant share of the polio market owing to increase in the number of programs for raising awareness regarding vaccination.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34049

Geographically, the market for polio is distributed over North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each geography market is sub-divided into specific countries such as the U.S., Canada, Germany, the U.K., Brazil, China, India, Japan, and GCC countries. North America is currently leading the polio market due to initiatives taken by the government for promoting the adoption of immunization programs against the polio disease and others such as influenza and HPV.

The target audiences of the global polio market include vaccine manufacturers, vaccine associations, clinical laboratories, vaccine research institutes, vaccine raw material suppliers, group purchasing organizations (GPOs), immunization centers, research and consulting firms, vaccine product distributors, biotechnology and biopharmaceutical companies, vaccine development institutes and organizations, and hospitals and laboratories.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34049

Key players operating in this market include GlaxoSmithKline, Merck & Co, Sanofi Pasteur, CSL Limited, Astellas Pharma Inc., Emergent BioSolutions, Inc., Johnson & Johnson, Pfizer, MedImmune, LLC, and Serum Institute India Pvt. Ltd.

Popular Research Reports by TMR:

Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

ACTH and GH Function Tests Market: Segmentation, Opportunities, Trends & Future Scope to 2025

Adenocorticotropic hormone (ACTH) is a hormone produced and secreted by the anterior pituitary gland. It is also called corticotropin or serum ACTH. The function of the ACTH is to regulate the level of steroid hormone cortisol, which is regulated by the adrenal gland. Growth hormone (GH) is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration. Growth hormone is also known as somatotropin or human growth hormone (HGH). Growth hormone is produced by the pituitary gland. It is a stress hormone that increases the levels of glucose and free fatty acids. ACTH is associated with diseases such as pituitary tumor and adrenal malfunction. GH is associated with acromegaly and gigantism. Hence, ACTH and GH testing is an important factor to control and cure diseases.

Report Overview @ https://www.transparencymarketresearch.com/acth-gh-function-tests-market.html

Rise in unhealthy lifestyle, growing stress levels, and unhealthy food habits that result in obesity that disturbs the levels of hormone are important factors likely to propel the global ACTH and GH function tests market during the forecast period. According to American Association of Neurological Surgeons, 10–15 persons per million people are affected every year with Cushing’s syndrome. Rise in the prevalence of Cushing syndrome and Addison disease is a major factor anticipated to fuel the global ACTH function tests market throughout the forecast period. Increasing prevalence of growth hormone deficiency (GHD) in children and rising prevalence of gigantism and child obesity are key factors likely to augment the global ACTH and GH function tests market during the forecast period. Additionally, rise in the prevalence of chronic diseases such as pituitary disorders, disturbing thyroid levels, high blood pressure, and increase in the prevalence of kidney disorders and hypogonadism are factors that are likely to drive the market from 2017 to 2025. According to the WHO, the number of diabetes patients worldwide would increase to 366 million by 2030, promoting rapid growth of the global ACTH and GH function tests market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33569

Based on technology, the global ACTH and GH function tests market has been divided into serology & immunoassays, molecular techniques, mass spectrometry, and others. The mass spectrometry segment is expected to register a high growth rate throughout the forecast period, due to advantages of mass spectrometry over traditional serology methods. Based on sample type, the market has been divided into blood, urine, and others. Based on end-user, the global ACTH and GH function tests market has been segregated into hospitals, diagnostic laboratories, ambulatory surgical centers, and other home care settings. The home care setting segment is anticipated to witness high between 2017 and 2025, due to cost-effective and user-friendly ACTH and GH function test kits offered under this segment.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33569

Based on geography, the ACTH and GH function tests market has been segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global ACTH and GH function tests market, both in terms of value and volume, followed by Europe. Developed hospitals, improved technology, increase in awareness about health care, and proper reimbursement are factors attributable to growth of the market in North America. The Asia Pacific market is expected to register a high growth rate during the forecast period, owing to factors such as developing health care network, improved hospital infrastructure, and rising awareness among people in the region.

Some of the key players operating in the global ACTH and GH function tests market are GenWay Biotech, Inc., LifeSpan BioSciences, Inc., Abcam plc, F. Hoffmann-La Roche Ltd, Abbott laboratories, and Laboratory Corporation of America. In order to maintain a significant position in the global market, major players are involved in launching highly efficient products and initiate collaborations and mergers. For example, Laboratory Corporation of America offers solutions for every hormonal disease. The company also offers Liquid Chromatography Mass Spectrometry (LC-MS), which requires a minimal amount of sample.

Popular Research Reports by TMR:

Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

Local Anesthetic Therapeutics Market Future Opportunities 2026

Global Local Anesthetic Therapeutics Market: Overview

Of late, the global local anesthetic therapeutics market has been witnessing remarkable surge in its market size. The increasing number of surgical procedures, such as cosmetic and dental procedures and plastic surgeries is the key factor behind the growth of this market. This research report is aimed at offering clear and in-depth information about the global market for local anesthetic therapeutics by carrying out a thorough analytical research of the performance of this market in the past and during the period from 2018 to 2026. The study especially highlights the growth boosters, obstacles, opportunities, challenges, and the key trends in this market in a bid to determine the pace of its growth.

Report Overview @ https://www.transparencymarketresearch.com/local-anesthetic-therapeutics-market.html

Global Local Anesthetic Therapeutics Market: Trends and Opportunities

The key trend observed in the global local anesthetic therapeutics market is significant surge in the demand for options for post-operative pain relief, on the back of the rising number of surgical procedures across the world. This trend is expected to continue over the next few years, reflecting positively on the demand for local anesthesia drugs. The rise in geriatric population, globally, is also projected to add to the growth of this market in the next couple of years. Going forward, the continual introduction of new drugs, such as levobupivacaine, articaine, and ropivacaine is likely to support the market in the near future.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45738

Global Local Anesthetic Therapeutics Market: Regional Outlook

On the basis of the geography, the worldwide local anesthetic therapeutics market can be divided into Latin America, Asia Pacific, Western Europe, Eastern Europe, North America, and the Middle East and Africa. Currently, North America is leading the global market, thanks to the availability of high diagnostic and research capabilities. Researchers expect this regional market to remain dominant over the next few years.

The Latin America market is led by Peru, Mexico, Brazil, and Chile, whereas, North America experiences the prominence of the U.S. and Canada in its local anesthetic therapeutics market. The Eastern European local anesthetic therapeutics market is led by Poland and Russia while Western European market for local anesthetic therapeutics is classified into the U.K., Belgium, Spain, France, Germany, Italy, Luxembourg, Netherlands, and Nordic countries. India, China, Australia, New Zealand, Japan, and ASEAN nations have surfaced as the dominant domestic markets for local anesthetic therapeutics market in Asia Pacific.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45738

Companies Mentioned in the Report

Aspen Pharmacare, Novartis Inc., Fresenius Kabi, Sagent Pharmaceutical, Mylan, Pacira Pharmaceutical, and Teva Pharmaceuticals are some of the main players in the global market for local anesthetic theraputics. Thanks to the presence of a large pool of vendors, the market is displaying a fragmented and a highly competitive structure. The leading players in this market are projected to focus especially on innovation and technological advancements in their offerings over the coming years in a bid to achieve a competitive edge over their rivals.

Popular Research Reports by TMR:

Pigmentation Disorders Treatment Market: https://www.prnewswire.com/news-releases/global-pigmentation-disorders-treatment-market-to-reach-us-9-268-6-mn-by-2026-rise-in-awareness-about-skin-rejuvenation-are-likely-to-boost-demand-transparency-market-research-828363328.html

Pediatric Medical Devices Market : https://www.prnewswire.com/news-releases/pediatric-medical-devices-market-to-become-worth-us-41-000-mn-by-2026-says-tmr-836720209.html

Transradial Access Devices Market Size & Share - Industry Trend and Forecast 2018 - 2026

Transradial access devices are widely used in coronary procedures to lower complications. Peripheral lesions can also be treated by transradial access devices. Transradial access devices are used for peripheral artery diseases such as atherosclerosis diseases of extra cranial carotid and vertebral, abdominal mesenteric, and renal as well as extremity arteries. The global transradial access devices market is driven by increase in adoption of interventional procedures with radial artery access devices, rise in prevalence of lifestyle diseases, surge in prevalence of obesity, increase in cardiovascular diseases, rise in awareness, and surge in demand for cardiovascular interventional procedures. However, stringent regulatory scenario, low reimbursement, and high cost of procedures are projected to restrain the global transradial access devices market.

Report Overview @ https://www.transparencymarketresearch.com/transradial-access-devices-market.html

The global transradial access devices market can be segmented based on product type, application, end-user, and region. In terms of product type, the global market can be classified into catheters, guidewires, sheaths and sheath introducers, and accessories. The catheters segment is expected to dominate the global transradial access devices market. Increase in number of non-invasive procedures due to rise in lifestyle disorders and surge in demand for interventional procedures which has fueled the demand for catheters. Based on application, the global transradial access devices market can be categorized into drug administration, fluid and nutrition administration, blood transfusion, and diagnostics and testing. The drug administration segment is anticipated to expand at a faster rate due to increased applications of transradial access devices for drug administration used in the treatment of infections and cancer. In terms of end-user, the global market can be divided into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to account for major market share due to large number of transradial procedures carried out in hospitals.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45477

In terms of region, the global transradial access devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to dominate the global transradial access devices market in terms of revenue from 2018 to 2026. Increase in incidence of chronic diseases and technological advancements in treatment options for diseases are the major factors contributing to the growth of the global transradial access devices market in North America and Europe. According to the American College of Cardiology, CVDs account for nearly 30% deaths across the globe every year and the total cost of CVD treatment is estimated at US$ 1,044 Bn by 2030. Nearly 790,000 individuals experience heart attack in the U.S. each year. Increase in incidence of cancer, cardiovascular diseases, infectious diseases, and lifestyle disorders in Asia Pacific present significant opportunities in the global transradial access devices market. Ischemic heart disease and stroke are the predominant causes of CVDs and responsible for over 80% deaths across the globe. The Global Burden of Disease study estimate of age-standardized CVD death rate of 272 per 100 000 population in India is higher than the global average of 235 per 100 000 population. The transradial access devices market in Asia Pacific is driven by the growing health care industry in countries such as India, technological advancement in Japan, and favorable reimbursement policies in Australia. Latin America and Middle East & Africa are emerging markets for transradial access devices due to increase in government intervention into health care and rise in awareness among the population.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45477

Major players in the global transradial access devices market are B. Braun, Changzhou Huida, DePuy Synthes, Evonos, Integra, Jeil Medical, KLS Martin, Medicon, Medtronic, Micromar, NEOS Surgery, OsteoMed, Pro Med Instruments, Stryker, and Zimmer Biomet, among others.

Popular Research Reports by TMR:

Medical Nonwoven Disposables Market :https://globenewswire.com/news-release/2018/08/08/1549072/0/en/Medical-Nonwoven-Disposables-Market-will-be-Worth-US-18-4-Billion-by-the-End-of-2024.html

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Immunohistochemistry Market Key Manufacturers, Development Trends And Competitive Analysis 2026

Global Immunohistochemistry Market: Overview

In the recent times, the global market for immunohistochemistry has observed a noticeable rise and is anticipated to experience an upswing in its valuation in the years to come. The significant rise in the prevalence of chronic diseases is likely to propel this market substantially over the next few years. This market study is a thorough analytical research of the performance of the worldwide market for immunohistochemistry in past and over the period from 2018 to 2026. The report emphasizes especially on the growth boosters, opportunities, challenges, obstacles, and the prominent trends in this market in a bid to determine the pace of its progress.

Report Overview @ https://www.transparencymarketresearch.com/immunohistochemistry-market.html

Global Immunohistochemistry Market: Key Trends and Opportunities

The global market for immunohistochemistry is benefiting substantially from the increasing prevalence of cancer and various other chronic diseases across the world. Apart from this, the alarming surge in the medical and healthcare spending and the shifting focus on value-based healthcare solutions are also supporting the growth of the global market, substantially. Going forward, the increasing uptake of advanced technologies in the medical and healthcare industries is likely to boost this market over the coming years.

Global Immunohistochemistry Market: Regional Outlook

The global market for immunohistochemistry is spread across North America, Asia Pacific (APAC), Eastern Europe, Western Europe, Latin America, and the Middle East and Africa (MEA). North America has been dominating this market, thanks to the rapid commercialization and the continual maturity of the biotech industry. However, the growth of this regional market will be hampered in the years to come, owing to the high investments due to lengthy research and development processes and approval cycles. Nonetheless, the increasing uptake of immunohistochemistry products in the diagnosis of tumors of uncertain origin is likely to support the North America market over the next few years, ensuring its dominance.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44952

On the other hand, the market for immunohistochemistry in Asia Pacific is projected to witness a high paced growth in the near future, thanks to the rapid advancements in the field of biotechnology in economies, such as Australia, Japan, India, and China. The rising prevalence of chronic diseases in this region is also expected to support the growth of the Asia Pacific market for immunochemistry over the forthcoming years.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=44952

Global Immunohistochemistry Market: Competitive Analysis

The global market for immunohistochemistry demonstrates a highly competitive business landscape with a significantly high number of participants. Thermo Fisher Scientific Inc., PerkinElmer Inc., Merck Millipore, F. Hoffmann-La Roche AG, Danaher Corp., Cell Signaling Technology Inc., Bio-Rad Laboratories Inc., Bio SB Inc., Agilent Technologies Inc., Abcam Plc, and CMR Naviscan Corp. are some of the leading players in this market. These companies are currently emphasizing on innovation and advancements in their products to remain relevant in this competitive environment. However, their focus is expected to shift towards strategic alliances in the years to come, in an effort to expand their reach across various regions.

Popular Research Reports by TMR:

Pigmentation Disorders Treatment Market: https://www.prnewswire.com/news-releases/global-pigmentation-disorders-treatment-market-to-reach-us-9-268-6-mn-by-2026-rise-in-awareness-about-skin-rejuvenation-are-likely-to-boost-demand-transparency-market-research-828363328.html

Pediatric Medical Devices Market : https://www.prnewswire.com/news-releases/pediatric-medical-devices-market-to-become-worth-us-41-000-mn-by-2026-says-tmr-836720209.html

Medical Robotics Market Growth Opportunities & Technology Developments by 2026

Medical robots help physicians perform surgeries with greater precision. Medical robotics is an emerging field of medical science that involves widespread use of telepresence and involves numerous operations. Robots are used in this discipline to execute operations normally executed manually by human beings. Robotics in health care is playing a critical role in revolutionizing the entire system and deliver better and improved services to patients. Use of these systems in the medical field has minimized individual oversight and utilization of telepresence in medical operations has eliminated the distance barrier and aided in taking specialized care to inaccessible areas without the need for physical travel.

Report Overview @ https://www.transparencymarketresearch.com/global-medical-robotics-market.html

A key factor contributing to the growth of the medical robotics market is the rising application of robotics systems in the medical field. Besides their use in surgery, these systems are increasingly being employed in pharmacy, clinical management, and elderly care. In pharmacy, robotics helps in relieving the supporting staff of monotonous duties, such as medication and workflow management. Globally, there has always been a shortage of medical staff, such as doctors and surgeons. According to the World Health Organization (WHO), there is a scarcity of around 4.3 million physicians in health care facilities. Based on a new study published by the Association of American Medical Colleges (AAMC), there is likely to be a shortage of 34,600 to 88,000 doctors in the U.S by 2025, which is expected to rise to 40,800 to 104,900 doctors by 2030. Telepresence robots can help in providing people accessibility to medical care in remote locations in the absence of physicians. In case of elderly people, robots can act as companions and make their life enjoyable and easier.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45135

Rise in investments in medical robotics is another factor propelling the growth of the global medical robotics market. In December 2015, the National Institutes of Health of the U.S. Department of Health and Human Services announced its decision to invest in the development of three innovative co-robots - robots that cooperatively work with people, out of which two robots are to be developed for improving health and quality of life of individuals with disabilities and the third one is to serve as social companion to individuals. The project as a part of National Robotics Initiative (NRI) will entail investments to the tune of US$ 2.2 million, spread over the next five years. Additionally, rise in investments in medical robots by health care providers, coupled with growing expenditure on health care globally, is projected to boost the growth of the global medical robotics market from 2018 to 2026. However, prohibitive prices of robotic systems and safety concerns raised over robotic surgery devices are likely to impede the growth of the market during the forecast period.

The global medical robotics market can be segmented based on product type, application, and geography. In terms of product type, the medical robotics market can be divided into surgical robots, rehabilitation robotic systems, noninvasive radiosurgery robotic systems, pharmacy robotic systems and others. Based on application, the medical robotics market can be classified into laparoscopy, orthopedics, neurology, and others.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45135

Geographically, the global medical robotics market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global medical robotics market due to rise in funding for research & development of new medical robotic systems, coupled with high adoption rate for these systems in the region’s health care system. North America is followed by Europe and Asia Pacific. Grant of approvals for medical robots in countries such as Japan is propelling the growth of the medical robotics market in Asia Pacific. In January 2018, Intuitive Surgical announced that it had received approval for 12 additional procedures in Japan for its da Vinci robot-assisted surgery devices. The procedures involved are additional colorectal, thoracic and gynecological surgeries, bladder cystectomies, plus gastrectomies, esophagectomies, and mitral valvuloplasty, which are in addition to prostatectomy and nephrectomy, already approved for robot-assisted surgeries in the country.

Prominent players operating in the global medical robotics market are Ekso Bionics Holdings, Inc., Intuitive Surgical, Inc., Stryker Corporation, Mazor Robotics Ltd., Accuray Incorporated, etc.

Popular Research Reports by TMR:

Pigmentation Disorders Treatment Market: https://www.prnewswire.com/news-releases/global-pigmentation-disorders-treatment-market-to-reach-us-9-268-6-mn-by-2026-rise-in-awareness-about-skin-rejuvenation-are-likely-to-boost-demand-transparency-market-research-828363328.html

Pediatric Medical Devices Market : https://www.prnewswire.com/news-releases/pediatric-medical-devices-market-to-become-worth-us-41-000-mn-by-2026-says-tmr-836720209.html

Wellness Tourism Market: Review with Forecast Research Report 2018 - 2026

Wellness tourism involves travel with the aim of facilitating well-being and good health through psychological, spiritual, or physical activities. Wellness tourism differs markedly from medical tourism. The former involves tourism focused on prevention of diseases and maintaining quality of life, whereas the latter generally involves travel for the purpose of receiving treatment for a diagnosed disease or medical condition. Wellness tourism encompasses diverse industries that enable consumers to incorporate wellness into their daily lives. These products and services help consumers extend wellness to their homes and work environments with their daily activities such as having food and exercise.

Report Overview @ https://www.transparencymarketresearch.com/wellness-tourism-market.html

A key factor driving the global wellness tourism market is the rise in disposable incomes, particularly in developing countries, owing to rapid growth of economies of these countries. Higher income levels have also shifted the trend toward increased discretionary spending, particularly on wellness goods and services. According to certain estimates, the average per capita disposable income in the Asia Pacific region increased by 19.3% from 2007 to 2012, which is slated to increase by 35.2% till 2020. Surge in the disposable income is expected to boost the demand for wellness tourism due to rise in the number of health-conscious people.

The growing burden of chronic diseases is a prominent factor promoting the growth of the global wellness tourism market. The increase in urbanization fueled by rapid economic growth has led to unbalanced diets and sedentary lifestyle. This, in turn, has augmented the prevalence of lifestyle-associated diseases such as obesity, diabetes, and high cholesterol. According to a study conducted by the Institute for Health Metrics & Evaluation (IHME), a global health research organization, in 2013, approximately 30% of the global population is either overweight or obese. The rise in disposable incomes is raising expenditure on fast food or junk food, causing surge in the prevalence of diseases such as diabetes. According to the World Health Organization (WHO), the number of individuals with diabetes worldwide increased to 422 million in 2014 from 108 million in 1980. The rate of prevalence of diabetes in people aged above 18 years has risen to 8.5% in 2014 from 4.7% in 1980. The WHO estimates that diabetes is projected to be the seventh leading cause of deaths worldwide by 2030.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45141

Additionally, people in countries such as the U.S., Brazil, and Mexico are increasingly resorting to wellness procedures such as beauty treatments, anti-aging treatments, weight loss programs, spa therapies, and yoga programs in order to boost their physical as well as mental well-being. The popularity of these programs coupled with the rise in stress levels is expected to propel the global wellness tourism market during the forecast period. On the other hand, shortage of facilities (for example, lack of adequate infrastructure and skilled and trained workers) in developing countries is expected to impede the market during the forecast period

The global wellness tourism market can be segmented based on service type and geography. In terms of service type, the market can be divided into beauty & anti-aging, health & nutrition, fitness & weight management, preventive & personalized medicine, complementary & alternative medicine, spa industry, workplace wellness, and others.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45141

Geographically, the global wellness tourism market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global wellness tourism market, due to high expenditure on wellness by consumers in the region. North America is followed by Europe and Asia Pacific. Rising disposable income of people in countries such as China, India, and Indonesia is propelling the wellness tourism market in Asia Pacific.

Prominent players operating in the global wellness tourism market are Four Seasons Hotels Limited, Hilton Worldwide, KPJ Healthcare Berhad, VLCC Health Care Limited, Hyatt Hotels Corporation, and Marriott International, Inc

Popular Research Reports by TMR:

Blood Group Typing Market: http://www.prnewswire.co.uk/news-releases/blood-group-typing-market-is-projected-to-reach-us-35560-mn-by-2026-says-tmr-691433291.html
Medical Nonwoven Disposables Market :https://globenewswire.com/news-release/2018/08/08/1549072/0/en/Medical-Nonwoven-Disposables-Market-will-be-Worth-US-18-4-Billion-by-the-End-of-2024.html

Patient Positioning Systems Market: Growth Analysis, Trends and Scope till 2026

Patient positioning system, also known as repositioning aid or device, is primarily used in health care facilities for mobility and repositioning of patients. Patient positioning systems are required for the elderly population for day-to-day activities, for those recovering from surgery or injury or any other medical condition, and also for those who are disabled permanently. These provide easy and safe way to move and transfer patients, and helping them to be more independent and mobile. These are also useful for children with birth defects or who are mentally challenged. Patient positioning systems are used during surgeries to maintain proper position of patient. A patient positioning system can be a complex electronic powered machine or a basic structure. These systems have wide applications in health care, especially in orthopedics, long term care centers, and general medical devices.

Report Overview @ https://www.transparencymarketresearch.com/patient-positioning-systems-market.html

The global patient positioning systems market can be segmented based on product type, application, end-user, and region. In terms of product type, the global market can be classified into tables, surgical tables, radiolucent imaging tables, examination tables, accessories, and other patient positioning systems. Based on application, the global patient positioning systems market can be categorized into surgery, diagnostics, and others. The surgery segment is expected to account for the largest share of the global patient positioning systems market. End-users of patient positioning systems are hospitals, clinics, ambulatory surgical centers, home care settings, and others. The hospitals segment is likely to account for the largest share of the market during the forecast period. This is attributed to requirement of patient positioning systems in hospitals because of high inflow of patients in hospitals and the need to transfer patients to various departments for procedures and examinations.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45063

Increase in demand for these systems in hospitals, development and advancement of products, and rise in global geriatric population drive the global patient positioning systems market. Other drivers include technological advancements in patient positioning systems and high or sudden rise in the number of mentally challenged patient hospitalization. Major restraints of the market are development of other substitute technologies and intense competition among existing product manufacturers. Moreover, product recalls, government regulations for reduction of overall health care cost, and subsequent upswing in bulk purchase through group purchasing organizations also restrain the market.

Geographically, the global patient positioning systems market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for major share of the global market due to advanced health care facilities and increase in use of patient positioning systems in orthopedic and physiotherapy departments of hospitals for patient recovery post treatment. The emerging markets in Asia Pacific, Latin America, and Middle East & Africa are estimated to witness strong growth during the forecast period. This is attributed to the growing health care industry, surge in investments by leading players operating in these countries, and the aging population. The patient positioning systems market in China, Brazil, and India is anticipated to grow at a rapid pace due to rise in investments by governments to improve hospitals and other health care facilities.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45063

The global patient positioning systems market is highly competitive due to the presence of numerous international and regional players. Key companies operating in the global market are Medtronic plc, Stryker Corporation, Hill-Rom Services, Inc., Medline Industries, OPT SurgiSystems Srl, Skytron, LLC, SchureMed, STERIS plc, Smith & Nephew, and LEONI Special Cables GmbH.

Popular Research Reports by TMR:

Orthopedic Devices Market: https://www.prnewswire.com/news-releases/orthopedic-devices-market-is-anticipated-to-reach-us-65-000-mn-by-2026-says-tmr-880357057.html

Hemoglobin A1c Testing Devices Market : https://globenewswire.com/news-release/2018/07/09/1534631/0/en/Global-Hemoglobin-A1c-Testing-Devices-Market-to-Exhibit-10-30-CAGR-Rising-Prevalence-of-Diabetes-Globally-to-Drive-Growth.html

ACTH and GH Function Tests Market Growth Opportunities & Technology Developments by 2025

Adenocorticotropic hormone (ACTH) is a hormone produced and secreted by the anterior pituitary gland. It is also called corticotropin or serum ACTH. The function of the ACTH is to regulate the level of steroid hormone cortisol, which is regulated by the adrenal gland. Growth hormone (GH) is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration. Growth hormone is also known as somatotropin or human growth hormone (HGH). Growth hormone is produced by the pituitary gland. It is a stress hormone that increases the levels of glucose and free fatty acids. ACTH is associated with diseases such as pituitary tumor and adrenal malfunction. GH is associated with acromegaly and gigantism. Hence, ACTH and GH testing is an important factor to control and cure diseases.

Report Overview @ https://www.transparencymarketresearch.com/acth-gh-function-tests-market.html

Rise in unhealthy lifestyle, growing stress levels, and unhealthy food habits that result in obesity that disturbs the levels of hormone are important factors likely to propel the global ACTH and GH function tests market during the forecast period. According to American Association of Neurological Surgeons, 10–15 persons per million people are affected every year with Cushing’s syndrome. Rise in the prevalence of Cushing syndrome and Addison disease is a major factor anticipated to fuel the global ACTH function tests market throughout the forecast period. Increasing prevalence of growth hormone deficiency (GHD) in children and rising prevalence of gigantism and child obesity are key factors likely to augment the global ACTH and GH function tests market during the forecast period. Additionally, rise in the prevalence of chronic diseases such as pituitary disorders, disturbing thyroid levels, high blood pressure, and increase in the prevalence of kidney disorders and hypogonadism are factors that are likely to drive the market from 2017 to 2025. According to the WHO, the number of diabetes patients worldwide would increase to 366 million by 2030, promoting rapid growth of the global ACTH and GH function tests market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33569

Based on technology, the global ACTH and GH function tests market has been divided into serology & immunoassays, molecular techniques, mass spectrometry, and others. The mass spectrometry segment is expected to register a high growth rate throughout the forecast period, due to advantages of mass spectrometry over traditional serology methods. Based on sample type, the market has been divided into blood, urine, and others. Based on end-user, the global ACTH and GH function tests market has been segregated into hospitals, diagnostic laboratories, ambulatory surgical centers, and other home care settings. The home care setting segment is anticipated to witness high between 2017 and 2025, due to cost-effective and user-friendly ACTH and GH function test kits offered under this segment.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33569

Based on geography, the ACTH and GH function tests market has been segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global ACTH and GH function tests market, both in terms of value and volume, followed by Europe. Developed hospitals, improved technology, increase in awareness about health care, and proper reimbursement are factors attributable to growth of the market in North America. The Asia Pacific market is expected to register a high growth rate during the forecast period, owing to factors such as developing health care network, improved hospital infrastructure, and rising awareness among people in the region.

Some of the key players operating in the global ACTH and GH function tests market are GenWay Biotech, Inc., LifeSpan BioSciences, Inc., Abcam plc, F. Hoffmann-La Roche Ltd, Abbott laboratories, and Laboratory Corporation of America. In order to maintain a significant position in the global market, major players are involved in launching highly efficient products and initiate collaborations and mergers. For example, Laboratory Corporation of America offers solutions for every hormonal disease. The company also offers Liquid Chromatography Mass Spectrometry (LC-MS), which requires a minimal amount of sample.

Popular Research Reports by TMR:

Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

Inactivated Vaccines Market Current Trends & Opportunities by 2025

A biological preparation that enhances or provides acquired immunity to a certain disease is known as vaccine. A vaccine contains an agent that resembles the disease-causing organism either in a weakened form (known as live attenuated vaccine), or in a killed form of the microbe or its protein (known as inactivated vaccine). Body’s immune system is stimulated by the agent, which is recognized as a foreign body by this immune system. The agent is then destroyed and remembered by the immune system. The vaccine agents are inactivated or killed in different ways to reduce infectivity in order to avoid vaccine infections.

Report Overview @ https://www.transparencymarketresearch.com/inactivated-vaccines-market.html

The global inactivated vaccines market is estimated to expand at a significant pace during the forecast period. The rising demand for inactivated vaccines from governments of industrialized and developing countries is a key factor driving the global inactivated vaccines market. Advantages of inactivated vaccines over live attenuated vaccines such as safety, stability, and lack of chances of pathogen reactivation can be passed on to immunocompromised people. These factors are likely to drive the global inactivated vaccines market during the forecast period. Furthermore, prevalence of infectious diseases and rise in awareness among people about immunization are other factors propelling the market. However, stringent government regulations regarding efficacy and safety and lack of supply of vaccines in remote areas are projected to be major restraining factors for the global inactivated vaccines market during the forecast period.

The global inactivated vaccines market can be segmented on the basis of product, method of inactivation, route of administration, and region. Based on product, the market can be divided into viral vaccines and bacterial vaccines. The viral vaccines segment is anticipated to hold a significant share of the global inactivated vaccines market from 2017 to 2025, due to increase in research on viruses and surge in the prevalence of viral diseases. Based on method of inactivation, the market can be divided into solvent detergent method, radiation method, pH concentration, heat inactivation, and others. The solvent detergent method segment is expected to hold a major share of the market between 2017 and 2025, due to operational flexibility offered by this method. Based on route of administration, the market can be divided into oral, subcutaneous, intravenous, and others.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31316

Geographically, the global inactivated vaccines market can be segregated into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the global inactivated vaccines market during the forecast period. Surge in investments by governments and high incidence of diseases in the region are a few factors propelling the market in North America. Furthermore, rise in awareness about vaccines, government programs, high health care expenditure are other factors fueling the market in the region. Europe is anticipated to hold a significant share of the global market between 2017 and 2025, due to increase in health care expenditure and surge in R&D activities in the region. The market in Asia Pacific is anticipated to witness rapid growth during the forecast period. Asia Pacific is a highly lucrative market for inactivated vaccines, due to high prevalence of diseases, government-induced national immunization programs, and increasing investments in R&D in the region.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=31316

In order to attain a significant position in the global inactivated vaccines market, key players are adopting strategies such as mergers and acquisitions, extensive R&D activities, introduction of cost-effective and efficient vaccine products, and collaborative partnerships. Some of the prominent players operating in the global inactivated vaccines market are Emergent BioSolutions, GlaxoSmithKline plc, Merck & Co., Inc., Seqirus, Sanofi, Valneva SE, Pfizer Inc., and Bharat Biotech.

Popular Research Reports by TMR:

Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

Borderline Personality Disorder Market: Global Segments, Top Key Players, Size and Recent Trends by Forecast to 2025

 

Borderline personality disorder (BPD), also known as cluster-B personality disorder, is a neurological health disorder. BPD affects the way a person feels and thinks about oneself and others. Common signs and symptoms of the disorder may include fear of abandonment, self-injuries such as suicidal tendency, intense anger, irritability, dangerous behavior, mood swings, identity disturbance, and chronic feelings of emptiness. Currently, there is no single cause of this disorder. BPD can be caused by a combination of factors such as genes and brain compounds or neurotransmitters. Neurotransmitters are brain chemical messengers that transmit essential information throughout the brain and body.

Report Overview @ https://www.transparencymarketresearch.com/borderline-personality-disorder-market.html

Neurological factors such as estrogen can lead to BPD. Varying estrogen cycles in women make them susceptible to the disorder. Self-injury, depression, and bipolar disorder are major complications of BPD. Borderline personality disorder is diagnosed by a mental health professional through the subject’s history, statistical manual, and procedures. Magnetic resonance imaging (MRI) is a test that uses for borderline personality disorder. Currently, there is no cure for borderline personality disorder; however, a few marketed drugs (antidepressants, mood stabilizers, and antipsychotics) are expected to help improve the symptoms of the disorder. Increasing prevalence of BPD across the globe is expected to drive the global borderline personality disorder market. Additionally, growing global awareness fuels the growth of the market. Multifactorial etiology and complex pathophysiology of the disorder are likely to be major restraints of the market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30647

The global borderline personality disorder market can be segmented based on treatment, end-user, and region. In terms of treatment, the market can be categorized into psychotherapy and drugs. BPD is primarily treated with psychotherapy. Psychotherapy is also called talk therapy, which is the fundamental treatment approach for this disorder. The primary focus of psychotherapy is to restore the current ability to function, manage emotions, and improve relationships. Psychotherapy can be segmented into dialectical behavior therapy (DBT), mentalization-based therapy (MBT), schema-focused therapy, and transference-focused therapy (TFP) and others. There is no approved drug for BPD; however, certain drugs could help reduce symptoms or co-occurring problems such as anxiety and depression. Drugs could include antipsychotics or mood-stabilizing and antidepressants. In terms of end-user, the borderline personality disorder market can be segmented into psychiatric hospital and home health care. In terms of revenue, the psychiatric hospital segment held a significant share of the market in 2016.

 

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30647

In terms of region, the global borderline personality disorder market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for the largest share of the global borderline personality disorder market in 2016, followed by Europe and Asia Pacific. The U.S. held a major share of the market in North America in terms of revenue. The market in Asia Pacific is expanding rapidly due to increase in number of patients. However, Asia Pacific is projected to be the most attractive market in the near future, especially emerging economies such as India, China, and Japan due to its better health care infrastructure, economic growth, increasing number of insurance payer, expanding and developing private health care sector, and increasing awareness among people.

Key players in the global borderline personality disorder market include Bristol-Myers Squibb, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, and Pfizer Inc.

Popular Research Reports by TMR:

Medical Sensors Market: https://www.prnewswire.com/news-releases/medical-sensors-market-to-be-worth-us-18-74-billion-by-2023-says-tmr-825051539.html

Foot Orthotic Insoles Market: http://www.prnewswire.co.uk/news-releases/foot-orthotic-insoles-market-to-surpass-a-value-of-us-50-bn-by-2026-says-tmr-690536631.html

Antimetabolite Drugs Market Growth, Capacity, Scope, Revenue, Key-Players, and Forecast until 2025

Antimetabolite is a chemical that inhibits a metabolite or interfere with metabolic pathways by enzymatic reaction. Antimetabolites are purine or pyrimidine analogs and folic acids. These chemicals are characterized by low molecular weight molecules and are one of the important chemotherapeutic agents. These chemicals have a similar structure like molecules used in nucleic acid synthesis. These are used as cancer therapeutics in leukemia, ovarian, and gastrointestinal cancers. The presence of these drugs has a negative impact on cell cycles as these drugs stop the cell growth and division; hence, these drugs are primarily used as chemotherapeutics in cancers. Antimetabolites are used in different applications such as trabeculectomy and antibiotics.

Report Overview @ https://www.transparencymarketresearch.com/antimetabolite-drugs-market.html

The global antimetabolite drugs market is expected to expand at a significant growth rate during the forecast period. According to the World Health Organization, cancer is the leading cause of morbidity and mortality globally which impacts about 14 million people annually, resulting in the rapid increase in research activities worldwide. This is one of the major factors attributed to the growth of the global antimetabolite drugs market during the forecast period. Increasing prevalence of unhealthy lifestyles such as cigarette smoking, pipes, cigar smoking, and continuous exposure to asbestos are major factors that can cause cancer, which in turn, are projected to drive the growth of the market. Furthermore, factors such as development in the fields of drug delivery and oncology, and increased government funding and initiative to create awareness about cancer diagnosis and treatment are expected to propel the growth of the global market in the next few years. However, factors such as lack of awareness about health in many developing countries, high cost of drugs, and adverse effects of chemotherapies are projected to restrain the growth of the global antimetabolite drugs market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37637

The global market for antimetabolite drugs is divided into type, application, and region. In terms of type, the global market is bifurcated into purine analogs, pyrimidine analogs, and folates. The folates segment is expected to account for a significant share of the global market since the drugs are more commonly used. In terms of application, the global market is divided into cancer therapeutics, antibiotics, and others. The cancer therapeutics segment is expected to dominate the global market during the forecast period. Factors such as high growing prevalence of cancer globally and high research activities in many regions are anticipated to fuel the segment growth.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37637

Geographically, the global market for antimetabolite drugs is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to account for a significant share of the global market during the forecast period due to factors such as rise in incidence of cancer, prevalence of unhealthy lifestyle, and increase in government funding. Furthermore, increasing health care expenditure, advanced technology, high research activities, and rise in awareness about cancer treatment are expected to boost the market growth in the region. Europe is anticipated to hold the second highest share of the global market. Asia Pacific is expected to register the highest growth rate during the forecast period due to factors such as growing health care expenditure, rising geriatric population, surge in disposable income, prevalence of chronic diseases, growing focus of global pharmaceutical companies toward the Asia Pacific region, and rising awareness about novel drugs for cancer treatment.

Key players operating in the global antimetabolite drugs market include Teva Parenteral Medicines, Inc., Fresenius Kabi Oncology Limited, Cadila Pharmaceuticals, Celon Laboratories Pvt. Ltd, and Eli Lilly and Company.

Popular Research Reports by TMR:

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Viral Inactivation Market: https://globenewswire.com/news-release/2018/08/24/1556475/0/en/Viral-Inactivation-Market-is-Projected-to-Surpass-US-5-736-bn-by-2025-Says-TMR.html

Small-molecule Injectable Drugs Market: Overview with Detailed Analysis, Competitive landscape Forecast to 2025

Injectable drug delivery is a process which involves the administration of a drug or combination of drugs into the patient’s body by using various delivery devices such as syringes and needles. It is important that injectable drugs should be sterilized before administration. Sterile injectable drugs are mostly prepared in the liquid form because easy transport of drugs directly systematic blood circulation. Sometimes, they may be prepared to transport the drug to a specific part of the body. The term ‘small molecule’ refers low-molecular-weight organic compound that can be administered orally or that can be injected. Small-molecule injectable drugs are used in the treatment of oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases.

Report Overview @ https://www.transparencymarketresearch.com/small-molecule-injectable-drugs-market.html

The global small-molecule injectable drugs market is expected to expand substantially during the forecast period, due to growth in the generic injectable is outpacing growth on the innovator side, strong pipeline in small-molecule injectable drug delivery, high R&D investment in related small molecule development from major players. In addition, increase in the incidence of chronic diseases, especially cancer and diabetes, across the world; rise in focus of drug manufacturers on research and development of anti-cancer drugs; increase in approval of new drugs for treatment of chronic diseases such as cancer drive the global small-molecule injectable drugs market. However, stringent rules and regulations in relation to facilities and equipment required for sterile small-molecule injectable drugs and high level of quality and care required in the production, storage, packaging, and distribution of small-molecule injectable drugs are projected to hamper the market during the forecast period. Setting up integrated facilities in high-potential markets and shortage in supply of sterile injectables have offered growth opportunities to manufacturers of small-molecule injectable drugs.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37313

The global small-molecule injectable drugs market has been segmented based on application, end-user, and region. Based on application, the global small-molecule injectable drugs market has been divided into oncology, anti-infective, blood disorders, hormonal diseases, diabetes, CNS, and others. The oncology segment dominates the global small-molecule injectable drugs market, due to rising use of small molecules in oncology. Based on end-user, the market has been segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.

Geographically, the global small-molecule injectable drugs market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region has been sub-divided into specific countries. North America dominates the global small-molecule injectable drugs market, owing to growing geriatric population, rising incidence of chronic and autoimmune diseases, and increasing demand for advanced medical technologies in the U.S. Asia Pacific is projected to be a highly attractive market during the forecast period, due to rising health care awareness and surging demand for advanced medical technologies in the region.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37313

Key players operating in the global small-molecule injectable drugs market are Amgen Inc., Baxter International Genentech, Inc., Novo Nordisk A/S. Johnson & Johnson, Sanofi S.A., Pfizer, Inc., GlaxoSmithKline Plc., AstraZeneca, and Merck & Co., Inc. In order to gain competitive advantage, major players are actively adopting various growth strategies. Collaborations, partnerships, agreements, and new product launches are some of these key strategies adopted by leading market players.

Popular Research Reports by TMR:

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Viral Inactivation Market: https://globenewswire.com/news-release/2018/08/24/1556475/0/en/Viral-Inactivation-Market-is-Projected-to-Surpass-US-5-736-bn-by-2025-Says-TMR.html

Solitary Fibrous Tumor (SFT) Treatment Market Size & Share - Industry Trend and Forecast 2017 - 2025

Solitary fibrous tumor (SFT) is a rare type of tumor. It generally comprises a spectrum of benign mesenchymal tumors that have thick collagen with hemangiopericytoma. Some of them can grow as malignant tumors. SFTs were first described in 1931 and they were recognized by several different names viz. pleural fibroma, benign mesothelioma, sub-serosal fibroma, localized fibrous tumor, benign mesothelioma, and solitary fibrous mesothelioma. Some of them are confused with sinonasal hemangiopericytoma. Sinonasal hemangiopericytoma are biologically, morphologically, and clinically very distinct from SFTs. They are thought to be intrathoracic tumors, whereas 50% to 60% of SFTs grow outside the thorax. Some of them develop in the central nervous system (CNS). Research findings suggest that solitary fibrous tumors usually affect adults (in mid-40s). They are observed equally in men and women. Some of them are observed in adolescents and children. The tumor site is broad and the tumor arises from visceral location. More than 40% of SFTs are localized in the subcutaneous tissues. Usually, dull pain and less growth are primary symptoms. These tumors can also cause hypoglycemia, as some of them exhibit production of insulin-like growth factors. About 15% to 20% of the malignant tumors may infiltrate and metastasize to a different location. Under microscope, these tumors show areas of collagen in combination with hemangiopericytoma and hypocelluarity. Typical SFTs show multinucleated giant cells with minimal cytoplasm and elongated nuclei.

Report Overview @ https://www.transparencymarketresearch.com/solitary-fibrous-tumor-treatment-market.html

The global solitary fibrous tumor (SFT) treatment market is estimated to expand rapidly in the next few years. Some of the driving factors for the market are increase in the incidence of cancers, rise in geriatric population worldwide, increase in awareness about cancer and its recurrence, technological advancements, and adoption of newly developed, minimally invasive techniques. Additionally, increase in investments by pharmaceutical and biotechnology companies to develop new molecular entities, advancements in chemotherapy, and better reimbursement policies in developed countries are a few key factors anticipated to augment the global solitary fibrous tumor (SFT) treatment market during the forecast period. However, side-effects caused by chemotherapy, increase in the cost of treatment, and lack of skilled professionals hinder the global solitary fibrous tumor (SFT) treatment market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37022

Based on type of treatment, the global solitary fibrous tumor (SFT) treatment market can be segmented into surgery, radiation therapy, and adjuvant chemotherapy. To date, research findings have not been able to figure out which treatment is superior. For example, if SFTs appear malignant, then adjuvant radiation therapy can be a good option. While in some of them, complete excision is generally preferred. After surgery or chemotherapy, long-term follow-up treatment is recommended by doctors, as distant or local relapse is possible, even in cases of benign tumors.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37022

Based on region, the global solitary fibrous tumor (SFT) treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is estimated to expand rapidly in the next few years, due to well-developed health care systems, proper reimbursement scenario, and adoption of new and advanced techniques in the region. North America is projected to be followed by Europe and Asia Pacific. Presence of key players, increase in investments in R&D by leading players, and alliance of key players with research institutes are some of the factors driving the global solitary fibrous tumor (SFT) treatment market.

Some of the key players operating in the global solitary fibrous tumor (SFT) treatment market are Medtronic Plc, AstraZeneca plc, Sun Pharmaceutical Industries Limited, Johnson & Johnson, Roche Ag, and Pfizer.

Popular Research Reports by TMR:

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Viral Inactivation Market: https://globenewswire.com/news-release/2018/08/24/1556475/0/en/Viral-Inactivation-Market-is-Projected-to-Surpass-US-5-736-bn-by-2025-Says-TMR.html

Blood Coagulation Factor Market: Overview with Detailed Analysis, Competitive landscape Forecast to 2025

The capability of our body cells to cease blood loss following a vascular injury by forming blood clot is vital to sustain health. Coagulation or clotting is the process of converting the liquid blood into a gel like clot to cease bleeding. A number of coagulation or clotting factors are involved in the route that leads to the physiological procedure called hemostasis. Hemostasis is the mechanism of clotting involving activation, adhesion, and aggregation of platelets mediated by a number of clotting factors eventually leading to repairing of the injured tissue. Any problem or absence of any of these factors can potentially lead to a rare but serious blood clotting disease and excessive bleeding. Some of the major coagulation factor disorders are the hemophilias and Von Willebrand disease.

Report Overview @ https://www.transparencymarketresearch.com/blood-coagulation-factor-market.html

The global blood coagulation factor market is anticipated to grow at a rapid pace owing to a multitude of factors. Blood coagulation factors falls under the infusible hemostats category. Developments in hemostasis technology has led to improvement of wide range of products that have enabled clinicians to provide proper emergency assistance to hemophilia patients. Factor VIII is a vital blood clotting protein in the human body. Its deficiency caused by a genetic defect results in a bleeding disorder called hemophilia A. Factor VIII concentrates are obtained from human plasma or via recombinant DNA technology to treat patients with hemophilia A. These factor therapies are infused intravenously through a vein in the arm or a port in the chest. Increase in the global trauma and accident cases is another driver of the blood coagulation factor market. Growth in the diagnosis rate of blood clotting diseases such as hemophilia and Von Willebrand disease is also expected to drive the global blood coagulation factor market during the forecast period. According to the data by published The Centers for Disease Control and Prevention (CDC), the incidence rate of hemophilia in the U. S. is 1 in every 5,000 male births. Von Willebrand disease (VWD), another bleeding disorder, is the most commonly occurring blood disorder that affects 1% of the population of the U.S. 1 in every 100 (almost 3.2 million) people in the U.S. is suffering from Von Willebrand disease (VWD). Huge number of patients with bleeding disorders increase the need for blood coagulation factor. Factor concentrates offer the most promising treatment results in these diseases. However, stringent regulatory policies and shortage in plasma supply can hamper the market growth during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36965

In terms of geography, the global blood coagulation factor market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to remain the dominant markets for blood coagulation factor market due to the high yield of plasma products, advancements in technology, and increasing number of patients with blood disorders. Asia Pacific is expected to expand at a high CAGR owing to the strong economic growth, increase in the disposable income, rise in the health care infrastructure, and growing investments by market players in this region. India has the highest number of hemophilia patients in the worlds. According to the Indian Genetic Disorder Database, there were an estimated 55,000 hemophilia patients in India in 2015, of these 60% to 70% remain undetected. Moreover, the birth rate hemophilia in India is 32 per 1,000 births. Huge number of patients with bleeding disorders in the country is expected to offer large opportunities in the blood coagulation factor market in India.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=36965

Key players operating in the global blood coagulation factor market include Baxter International Inc, CSL Ltd., Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, and Octapharma AG.

Popular Research Reports by TMR:

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Viral Inactivation Market: https://globenewswire.com/news-release/2018/08/24/1556475/0/en/Viral-Inactivation-Market-is-Projected-to-Surpass-US-5-736-bn-by-2025-Says-TMR.html